Is vancomycin FDA-approved, and what does the research show?

What is vancomycin?

Vancomycin is an antibiotic, a drug that kills bacteria, and FDA's label classes it as a glycopeptide antibacterial ¹. A glycopeptide is a ring of amino acids with sugars attached, which is why the name turns up on peptide lists. It is a large molecule; its hydrochloride salt has a molecular weight of about 1,486 ¹.

It is not a hormone, a signaling peptide or a wellness product. The uses on its label are bacterial infections, and the label says antibacterial drugs do not treat viral infections such as the common cold ¹. In the United States it is sold as a frozen premixed injection, as vials for infusion, and as oral forms under names that include Vancocin and Firvanq ¹, ⁵, ⁴.

Is vancomycin FDA-approved?

Yes. Vancomycin is approved by FDA as a prescription antibiotic, with "Initial U.S. Approval: 1958" on the injection's label ¹, ⁶. The label approves the injection "for the treatment of the following infections in adult and pediatric patients for whom appropriate dosing with this formulation can be achieved" ¹. Those are septicemia, infective endocarditis, skin and skin structure infections, bone infections and lower respiratory tract infections ¹.

Septicemia is infection of the bloodstream, and infective endocarditis is infection of the heart's valves or lining. The label ties the uses to named bacteria: susceptible isolates of MRSA and, for most uses, coagulase-negative staphylococci, a related group of staph bacteria ¹. The label also covers methicillin-susceptible staphylococci in people allergic to penicillin, or who cannot take or have not responded to other drugs such as penicillins or cephalosporins ¹. For endocarditis it adds viridans group streptococci, Streptococcus gallolyticus, Enterococcus and Corynebacterium species, some in combination with other antibiotics ¹. The label tells prescribers to use it "only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria" ¹.

The label is Baxter Healthcare's, for the premixed injection, filed as new drug application (NDA) 050671 and approved April 29, 1993; the 1958 date is the label's "Initial U.S. Approval" for the drug itself ¹, ⁶. Drugs@FDA, FDA's public register of approved drugs, gives all five strengths the marketing status "Prescription" as of November 9, 2026, the date of its data ⁶. Its latest labeling supplement was approved June 9, 2026 ⁶. Drugs@FDA holds 67 applications for products with vancomycin hydrochloride as the active ingredient, 61 of them generic applications ⁵.

A separate oral product exists for a different job. Vancocin capsules, NDA 050606, were first approved April 15, 1986 ⁵. They are indicated for diarrhea caused by the gut bacterium Clostridioides difficile and for enterocolitis, inflammation of the bowel, caused by Staphylococcus aureus ⁴. That label's limitations say vancomycin given by vein "is not effective for the above infections," and vancomycin taken by mouth "is not effective for other types of infections" ⁴. The route to either product is a clinician's prescription ⁶, ⁵.

See the FDA status of every peptide, updated weekly.

How does vancomycin work?

Vancomycin kills bacteria mainly by blocking the building of their cell wall; the label adds that it alters the bacterial cell membrane's permeability and RNA synthesis ¹. It acts on gram-positive bacteria ¹, the group whose thick cell wall takes up a violet stain in the laboratory test that gives the group its name. The label states it is not active in the test tube against gram-negative bacilli, mycobacteria or fungi, and that there is no cross-resistance between vancomycin and other antibacterials ¹.

The label lists the bacteria against which vancomycin is active "both in vitro and in clinical infections" ¹. They are staphylococci including MRSA, enterococci, viridans group streptococci, Streptococcus gallolyticus and Corynebacterium species ¹. With an aminoglycoside, another antibiotic class, the two together act more strongly in the test tube against many of these than either alone ¹.

In people with normal kidneys about three quarters of a dose leaves in the urine within 24 hours, and no metabolism of it is apparent ¹. Its half-life in plasma, the time for the blood level to fall by half, is 4 to 6 hours with normal kidney function ¹. It is 7.5 days in people whose kidneys do not work ¹.

What does the research show?

FDA has approved vancomycin since 1958, so its evidence level is "Approved for a use" ¹. The 2026 injection label carries no clinical studies section; it states the drug's activity in clinical infections and its microbiology, pharmacology and safety record ¹. In animal models, the label says, its activity for certain germs, including MRSA, appears to track the ratio of drug exposure to the concentration that stops a germ's growth ¹. The measure best tied to cure in people "has not been elucidated in clinical trials" ¹.

Two randomized trials measured newer antibiotics against vancomycin as the standard. Studied in people against daptomycin: a randomized trial published in August 2006 enrolled 246 patients with Staphylococcus aureus bacteremia, bacteria in the bloodstream, with or without endocarditis ², ⁷. It was open-label, meaning patients and doctors knew the treatment ⁷. It assigned 124 to daptomycin and 122 to standard therapy, defined as initial low-dose gentamicin, another antibiotic, plus either a penicillin that acts on staph or vancomycin ². The trial ran at many centers from March 2002 to February 2005, sponsored by Cubist Pharmaceuticals ⁷.

Treatment success 42 days after the end of therapy was 53 of 120 on daptomycin and 48 of 115 on standard therapy ². That is 44.2 against 41.7 percent, and daptomycin met the trial's test of being no worse ². Clinically significant kidney dysfunction was more frequent on standard therapy than on daptomycin ². The authors note that reduced susceptibility to vancomycin was seen in isolates from patients treated with vancomycin ². The standard arm mixed penicillin and vancomycin, so its figures are the arm's, not vancomycin's alone ².

Studied in people against linezolid: a randomized trial published online in January 2012 enrolled hospitalized adults with MRSA pneumonia acquired in hospital or in health care ³. It was double-blind, meaning neither patients nor doctors knew the treatment ³. It treated 1,184 patients and reports its results for the 448 in its modified intention-to-treat population and the 348 who completed treatment as planned ³.

In the per-protocol analysis, clinical success at the end of the study was 81 of 174 on vancomycin, 46.6 percent, against 95 of 165 on linezolid, 57.6 percent ³. Death from any cause within 60 days was similar, 17.0 percent on vancomycin and 15.7 percent on linezolid ³. Kidney toxicity was more frequent on vancomycin than on linezolid, with vancomycin dosed by blood levels ³.

The studies cited here all test it against bacterial infection ², ¹, ⁴, ³. The label says prescribing it without a proven or strongly suspected bacterial infection or a reason to prevent one "is unlikely to provide benefit" and raises the risk of drug-resistant bacteria ¹. The label also states that no long-term animal studies of cancer risk and no definitive fertility studies have been done ¹.

What are the side effects?

The label's highlights name "the most common adverse reactions" as anaphylaxis, "vancomycin infusion reaction," acute kidney injury, hearing loss and neutropenia ¹. Anaphylaxis is a severe whole-body allergic reaction, and neutropenia is a fall in infection-fighting white cells.

Rapid infusion can bring low blood pressure "including shock and cardiac arrest," wheezing, breathlessness, hives, and muscle and chest pain ¹. The "vancomycin infusion reaction" is itching and redness of the face, neck and upper body, or pain and muscle spasm of the chest and back ¹. Reports say it is more frequent when anesthetic agents are given at the same time ¹. The label has prescribers infuse it slowly to reduce that risk ¹.

Vancomycin "can result in acute kidney injury," mainly through interstitial nephritis, inflammation of the tissue between the kidney's tubules, and the label requires blood-level and kidney monitoring in every patient ¹. The risk rises with higher blood levels, longer exposure, other kidney-toxic drugs, the antibiotic combination piperacillin-tazobactam, dehydration, existing kidney disease and critical illness ¹. In the daptomycin trial, significant kidney dysfunction occurred in 26.3 percent of the standard-therapy arm against 11.0 percent on daptomycin ². In the linezolid trial, kidney toxicity occurred in 18.2 percent on vancomycin against 8.4 percent on linezolid ³.

Hearing damage "may be reversible or permanent," showing as ringing in the ears, hearing loss, dizziness or vertigo ¹. The risk is higher in older patients, at higher doses, with existing hearing loss, with another ear-toxic drug and with kidney impairment ¹. Severe skin reactions, including toxic epidermal necrolysis and Stevens-Johnson syndrome, have been reported ¹. Diarrhea from Clostridioides difficile "has been reported with use of nearly all antibacterial agents," including this one, and "may range in severity from mild diarrhea to fatal colitis" ¹. Reversible neutropenia has been reported in "several dozen patients," usually after a week or more of treatment ¹.

Permanent loss of vision from a retinal condition, hemorrhagic occlusive retinal vasculitis, occurred when vancomycin was put into the eye during or after cataract surgery ¹. The label says the intravitreal route "has not been approved and is not recommended," and the drug is not indicated to prevent eye infection after surgery ¹. The label calls vancomycin "irritating to tissue," reports inflammation and clots at infusion sites, and says injection into muscle causes pain and tissue death ¹. The sodium chloride bags carry sodium, so the label says to avoid them in congestive heart failure, in elderly patients and in people on a sodium-restricted diet ¹. Post-marketing reports add a shortage of blood to the heart muscle during an allergic reaction, and hemolytic anemia, in which red blood cells break down ¹.

The label carries no boxed warning ¹. Contraindications are the cases in which a drug must not be given. The label's are a known allergy to vancomycin and, for the dextrose bags, possibly a known allergy to corn or corn products ¹. On pregnancy, the label says several decades of data "have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes" ¹.

In sport

Vancomycin is not named on WADA's 2026 Prohibited List ⁸. WADA is the World Anti-Doping Agency, whose list governs tested athletes. The list also prohibits methods, and one concerns infusions of any drug ⁸. M2.2 prohibits "Intravenous infusions and/or injections of more than a total of 100 mL per 12-hour period except for those legitimately received in the course of hospital treatments, surgical procedures or clinical diagnostic investigations" ⁸.

What JumpstartMD offers

JumpstartMD does not prescribe vancomycin. Our peptide library covers it so you have the facts on its FDA status and the evidence, current as of November 10, 2026.

Ready to talk?

Book FREE Consultation

Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.

Share your details and a JumpstartMD team member will reach out when we open.

Disclaimer

Compounded medications are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before they are marketed. A licensed clinician decides after an evaluation whether a peptide is appropriate for you, and not every patient will qualify.